Vapotherm logo
Vapotherm VAPO
report update icon

Quarterly report 2024-Q2
added 05-23-2026

Vapotherm Income Statement 2023-2011 | VAPO

Brief overview of financial performance at Vapotherm

The figures are compared over a five-year interval. The revenue attributed to Vapotherm moved from $11.7 million to $68.7 million between the two endpoints. The total change was +487.6%, with a CAGR of approximately 42.5%. Revenue growth reflects a pronounced phase of business expansion.

At the gross-profit level, the result moved from 4.8 million dollars to 28.3 million dollars, a change of +487%. Cost of revenue moved broadly in line with sales. The gross margin was 41.2% at the start and 41.2% at the end. There was no meaningful shift in gross profitability.

The operating result measured by EBITDA moved from −8.8 million dollars to −34.1 million dollars, or −289%. Operating performance weakened relative to revenue. The EBITDA share of revenue changed from −75% to −49.7%. The business generated more EBITDA from each unit of revenue.

The net financial result changed from −12.9 million dollars to −58.2 million dollars. Larger losses indicate rising pressure on the business.

The market value of the business moved from $48.9 million to $7.7 million, or −84.3%. Financial performance is stronger than the share-price trend.

Overall conclusion

The current trajectory does not yet confirm a sustainable recovery. Key strengths include revenue expansion, positive operating leverage and steady gross profitability. The main areas of concern are declining net profitability, a weaker market valuation and limited operating profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement Vapotherm

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

7.67 M 3.14 M 419 M 823 M 194 M 48.9 M - - - - - - -

Shares

6.04 M 3.34 M 25.9 M 23.8 M 18.6 M 2.91 M - - - - - - -

Historical Prices

1.27 0.94 16.2 34.5 10.4 16.8 - - - - - - -

Net Income

-58.2 M -113 M -59.8 M -51.5 M -51.1 M -12.9 M -31 M -23.1 M - - - - -

Revenue

68.7 M 66.8 M 113 M 126 M 48.1 M 11.7 M 35.6 M 30.1 M - - - - -

Cost of Revenue

40.4 M 49.6 M 60.1 M 62.7 M 26.8 M 6.87 M - - - - - - -

Gross Profit

28.3 M 17.2 M 53.2 M 63 M 21.3 M 4.82 M 13.2 M 9.94 M - - - - -

Operating Income

-39.1 M -100 M -57.2 M -43 M -48.2 M -10.9 M - - - - - - -

Interest Expense

18.7 M 11.6 M 2.6 M 4.71 M 5.1 M 3.06 M - - - - - - -

EBITDA

-34.1 M -95.2 M -51.5 M -38.2 M -45.1 M -8.77 M -27 M -20.9 M - - - - -

Operating Expenses

67.4 M 118 M 110 M 106 M 69.5 M 15.8 M 41.8 M 32.2 M - - - - -

General and Administrative Expenses

19.3 M 27.8 M 31.4 M 24 M 18.4 M 3.4 M 8.02 M 5.94 M - - - - -

All numbers in USD currency

Quarterly Income Statement Vapotherm

2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

6.44 M 6.43 M 6.17 M 6.36 M 50.6 M 40.6 M 3.56 M 26.7 M 26.6 M 26.3 M 26.1 M 26 M 25.9 M 25.8 M 25.7 M 25.6 M 23.1 M 20.9 M 20.9 M 19.5 M 17.1 M 16.9 M 16.8 M 875 K 838 K 786 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-14.3 M -14.8 M - -15.1 M -14.8 M -18.1 M - -26.2 M -42.7 M -22.9 M - -13.6 M -17.3 M -10.4 M -17.2 M -12.4 M -8.03 M -13.8 M -12.4 M -12.8 M -12.9 M -13 M -12.9 M -9.46 M -11.2 M -8.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

16.9 M 19.1 M - 15.2 M 16 M 17.7 M - 13.5 M 13 M 21.6 M - 38.1 M 20.6 M 32.3 M 40.9 M 30.6 M 35.2 M 19.1 M 13 M 10.8 M 12 M 12.3 M 11.7 M 9.39 M 10.6 M 10.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

8.6 M 9.48 M - 9.15 M 9.18 M 11.5 M - 11.7 M 10.6 M 13.7 M - 19.3 M 11.2 M 15.1 M 20.2 M 15 M 17.5 M 9.9 M 7.15 M 6 M 6.53 M 7.12 M 6.87 M 5.77 M 6.47 M 6.49 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

8.28 M 9.66 M - 6.01 M 6.86 M 6.21 M - 1.86 M 2.36 M 7.89 M - 18.8 M 9.41 M 17.2 M 20.7 M 15.5 M 17.6 M 9.22 M 5.86 M 4.81 M 5.46 M 5.18 M 4.82 M 3.62 M 4.09 M 4.24 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-9.27 M -5.58 M - -10.3 M -10.2 M -13.6 M - -22.9 M -39.8 M -19.9 M - -12.9 M -16.6 M -9.7 M -12.3 M -11.2 M -6.77 M -12.7 M -12.7 M -11.6 M -11.7 M -12.1 M -10.9 M -8.73 M -9.15 M -8.42 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

4.94 M 9.25 M - 4.83 M 4.64 M 4.33 M - 3.28 M 2.85 M 1.75 M - 647 K 648 K 665 K -4.87 M 1.31 M 1.3 M 1.3 M 121 K 1.34 M 1.42 M 1.02 M -1.94 M 908 K 498 K 616 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-6.74 M -4.28 M - -6.58 M -7.71 M -12.4 M - -18.9 M -37.1 M -18.5 M - -8.7 M -13.7 M -8.13 M -12.3 M -7.84 M -4.62 M -11.6 M -12.7 M -9.42 M -11 M -11.5 M -10.9 M -7.17 M -8.65 M -7.95 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

17.6 M 15.2 M - 16.3 M 17 M 19.8 M - 24.8 M 42.2 M 27.8 M - 31.7 M 26 M 26.9 M 33 M 26.7 M 24.4 M 21.9 M 18.6 M 16.5 M 17.1 M 17.3 M 15.8 M 12.3 M 13.2 M 12.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

3.77 M 4.47 M - 4.43 M 5.02 M 5.77 M - 6.48 M 5.32 M 8.95 M - 7.26 M 8.63 M 8.06 M 7.11 M 6.05 M 5.63 M 5.25 M 5.02 M 3.98 M 4.53 M 4.88 M 3.4 M 2.8 M 2.6 M 2.38 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Vapotherm (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 57.08 3.84 % $ 8.66 B usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 15.55 0.18 % $ 440 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 8.8 6.24 % $ 642 M israelIsrael
Electromed Electromed
ELMD
$ 29.6 0.27 % $ 245 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.71 0.69 % $ 12 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 80.32 0.36 % $ 4.38 B britainBritain
LENSAR LENSAR
LNSR
$ 8.3 0.24 % $ 99.3 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.34 0.15 % $ 21.2 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Butterfly Network Butterfly Network
BFLY
$ 8.43 0.93 % $ 2.08 B usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 125.33 0.02 % $ 4.35 B usaUSA